




ATC codes: **N05AX08**

ICD11 code: **6A4Z**

|                          |   |
|--------------------------|---|
| Indication               | Schizophrenia or other primary psychotic disorders  |
| INN                      | Risperidone   |
| Medicine type            | Chemical agent  |
| List type                | Core  |
| Formulations             | Oral > Solid: 0.25 mg ; 0.5 mg ; 1 mg ; 2 mg ; 3 mg ; 4 mg ; 6 mg   |
| EML status history       | First added in 2013 (TRS 985)<br>Changed in 2023 (TRS 1049)   |
| Sex                      | All   |
| Age                      | Adolescents and adults  |
| Therapeutic alternatives | aripiprazole (ATC codes: N05AX12)<br>olanzapine (ATC codes: N05AH03)<br>paliperidone (ATC codes: N05AX13)<br>quetiapine (ATC codes: N05AH04)                              |
| Patent information       | Patents have expired in most jurisdictions<br>Read more <a href="#">about patents</a> .  |
| Wikipedia                | <a href="#">Risperidone</a>   |
| DrugBank                 | <a href="#">Risperidone</a>    |

## Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the addition of a square box to the listing of risperidone on the EML for treatment of schizophrenia and related chronic psychotic disorders, specifying oral aripiprazole, olanzapine, paliperidone and quetiapine as therapeutic alternatives. The Committee noted that evidence from several high-quality meta-analyses on the acute and maintenance treatment of schizophrenia and other chronic psychoses that found most oral second-generation antipsychotics were similarly effective and tolerable.

